Polymer Nanoparticle Polyplexes for Peptide Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide-based cancer vaccines face challenges in inducing effective immune responses due to the unpredictability of peptide sequences and their physical and chemical diversity, leading to variable responses and toxicity, especially when using soluble peptide antigens.
Innovation Solution
The development of immunogenic compositions comprising polymer nanoparticles that complex peptide antigens through electrostatic interactions, incorporating a peptide tag and an adjuvant, which form stable polyplexes that can be taken up by immune cells to induce an immune response, overcoming the limitations of soluble peptide antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If soluble peptide antigens are used in peptide-based cancer vaccines, then the vaccine can be formulated and administered, but the immune response is variable and toxicity occurs due to unpredictable peptide sequences and physical/chemical diversity
Solution Approach 1:
The patent changes the physical state parameter of the peptide antigen from soluble to insoluble form. By converting the peptide antigen into an insoluble formulation (e.g., through aggregation or association with adjuvants), the vaccine achieves more consistent and predictable immune responses while maintaining ease of manufacture. This parameter change resolves the contradiction by eliminating the variability associated with soluble peptide sequences.
2Device complexity
If soluble peptide antigens are used, then the vaccine formulation is simple, but toxicity increases due to immune activation against normal cells
Solution Approach 1:
The patent applies parameter changes by altering the solubility state of the peptide antigen from soluble to insoluble. This transformation reduces toxicity by preventing non-specific immune activation against normal cells while maintaining formulation simplicity. The insoluble form of the peptide antigen delivers the immune stimulus more selectively, thereby reducing harmful effects.
3Adaptability or versatility
If peptide-based vaccines are used to target tumor neoantigens, then individualized vaccine approaches can be developed, but the broad physical and chemical diversity of peptide sequences makes formulation strategies unpredictable
Solution Approach 1:
The patent resolves the contradiction between adaptability and formulation predictability by changing the physical parameter of the peptide antigen from soluble to insoluble. This parameter change creates a standardized delivery platform that works across different peptide sequences, making formulation strategies predictable while maintaining the ability to target individualized neoantigens.
Solution Approach 2:
The patent introduces an intermediary substance (such as an adjuvant or carrier protein) that mediates between the diverse peptide sequences and the immune system. This intermediary creates a consistent formulation platform that can accommodate various peptide antigens while providing predictable immune responses, thereby resolving the contradiction between individualization and predictability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the immunogenicity of soluble peptide antigens by stabilizing them into nanoparticles, improving immune response induction and reducing toxicity, thereby providing a more effective and scalable cancer vaccine strategy.
Implementation Method 1
The conjugate comprises a peptide antigen linked to a peptide tag, optionally via a linker. Charge neutralization between the peptide tag and polymer of opposite charge results in formation of polymer nanoparticles including a complex of peptide antigen and polymer
Data Source
AI summary
Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.